Circulating 25-hydroxyvitamin D and the risk of rarer cancers: Design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.
The Cohort Consortium Vitamin D Pooling Project of Rarer Cancers (VDPP), a consortium of 10 prospective cohort studies from the United States, Finland, and China, was formed to examine the associations between circulating 25-hydroxyvitamin D (25(OH)D) concentrations and the risk of rarer cancers. Cases (total n = 5,491) included incident primary endometrial (n = 830), kidney (n = 775), ovarian (n = 516), pancreatic (n = 952), and upper gastrointestinal tract (n = 1,065) cancers and non-Hodgkin lymphoma (n = 1,353) diagnosed in the participating cohorts. At least 1 control was matched to each case on age, date of blood collection (1974-2006), sex, and race/ethnicity (n = 6,714). Covariate data were obtained from each cohort in a standardized manner. The majority of the serum or plasma samples were assayed in a central laboratory using a direct, competitive chemiluminescence immunoassay on the DiaSorin LIAISON platform (DiaSorin, Inc., Stillwater, Minnesota). Masked quality control samples included serum standards from the US National Institute of Standards and Technology. Conditional logistic regression analyses were conducted using clinically defined cutpoints, with 50-<75 nmol/L as the reference category. Meta-analyses were also conducted using inverse-variance weights in random-effects models. This consortium approach permits estimation of the association between 25(OH)D and several rarer cancers with high accuracy and precision across a wide range of 25(OH)D concentrations.
Gallicchio
Lisa
L
Mercy Medical Center, Baltimore, Maryland 21202, USA. lgallic@mdmercy.com
Helzlsouer
Kathy J
KJ
Chow
Wong-Ho
WH
Freedman
D Michal
DM
Hankinson
Susan E
SE
Hartge
Patricia
P
Hartmuller
Virginia
V
Harvey
Chinonye
C
Hayes
Richard B
RB
Horst
Ronald L
RL
Koenig
Karen L
KL
Kolonel
Laurence N
LN
Laden
Francine
F
McCullough
Marjorie L
ML
Parisi
Dominick
D
Purdue
Mark P
MP
Shu
Xiao-Ou
XO
Snyder
Kirk
K
Stolzenberg-Solomon
Rachael Z
RZ
Tworoger
Shelley S
SS
Varanasi
Arti
A
Virtamo
Jarmo
J
Wilkens
Lynne R
LR
Xiang
Yong-Bing
YB
Yu
Kai
K
Zeleniuch-Jacquotte
Anne
A
Zheng
Wei
W
Abnet
Christian C
CC
Albanes
Demetrius
D
Bertrand
Kimberly
K
Weinstein
Stephanie J
SJ
D000328:Adult; D016022:Case-Control Studies; D002681:China / Q000453:epidemiology; D015331:Cohort Studies; D016889:Endometrial Neoplasms / Q000453:epidemiology / Q000517:prevention & control; D004938:Esophageal Neoplasms / Q000453:epidemiology / Q000517:prevention & control; D005260:Female; D005387:Finland / Q000453:epidemiology; D006801:Humans; D007680:Kidney Neoplasms / Q000453:epidemiology / Q000517:prevention & control; D016015:Logistic Models; D008228:Lymphoma, Non-Hodgkin / Q000453:epidemiology / Q000517:prevention & control; D008297:Male; D015201:Meta-Analysis as Topic; D009369:Neoplasms / Q000517:prevention & control*; D010051:Ovarian Neoplasms / Q000453:epidemiology / Q000517:prevention & control; D010190:Pancreatic Neoplasms / Q000453:epidemiology / Q000517:prevention & control; D011446:Prospective Studies; D012107:Research Design; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000453:epidemiology / Q000517:prevention & control; D014481:United States / Q000453:epidemiology; D014807:Vitamin D / Q000097:blood* / Q000627:therapeutic use*; D014808:Vitamin D Deficiency / Q000150:complications* / Q000453:epidemiology / Q000517:prevention & control
D014807:Vitamin D